

SoonerCare

CURE HEPATITIS C INITIATIVE

In March 2023, the Biden Administration announced a national strategic plan to eliminate viral hepatitis as a public health threat in the United States by 2030: **A Roadmap to Elimination**.

Priority Populations¹

Incidence: People who inject drugs, American Indian/Alaskan Native

Prevalence: People who inject drugs, Black, non-Hispanic, people born between 1945-1965, people with HIV

Mortality: American Indian/Alaska Native, Black, non-Hispanic, people born between 1945-1965

Universal Screening Saves Lives⁴

The CDC recommends universal hepatitis C screening for:

- Every person 18+ (at least once)
- All pregnant people (during each pregnancy)
- Every person with risk factors (at least once and periodically if ongoing)

*In settings where prevalence is 0.1% or greater

Medication Coverage⁵

Hepatitis C (HCV) can be CURED in 8 weeks with MAVYRET® for most patients.

MAVYRET (glecaprevir/pibrentasvir) is the only SoonerCare preferred direct-acting antiviral (DAA) medication for HCV and is now available to SoonerCare members without a prior authorization (PA) and does not require a specialist consult!

The American Association for the Study of Liver Disease (AASLD) and Infectious Disease Society of American (IDSA) have developed **HCV Treatment Guidelines**.

All other DAA PA criteria and forms are still in effect for SoonerCare. There are supports in place to assist with specialist consultations, CME and care management for hepatitis C treatment through the **OSU Hepatitis C TeleECHO**.

Did you know?

According to the CDC, hepatitis C rates nearly tripled from 2011-2018!²

In the 2018 surveillance report by the CDC, across the nation there were 3,621 new cases reported, 1.2 cases per 100,000 population, 50,300 acute infections estimated.

In Oklahoma, there are approximately 4,500 SoonerCare members with a diagnosis of hepatitis C that are untreated.³



OKLAHOMA
Health Care Authority

1. *Viral Hepatitis National Strategic Plan Overview (hhs.gov)*
2. *Hepatitis C Surveillance in the United States, 2018 (cdc.gov)*
3. *Chronic Conditions - Hepatitis - SFY2020.pdf (oklahoma.gov)*
4. *HepC_ScreeningRecs_Factsheet.pdf (cdc.gov)*
5. *Mavyret letter final.pdf (oklahoma.gov)*